http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004000229-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_634d7355c2673489b2f4f800541770bb
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-175
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02
filingDate 2003-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5db5906810d1ffd274b6d129aa4a8f95
publicationDate 2004-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2004000229-A3
titleOfInvention Treatment of human multiple myeloma by curcumin
abstract All multiple myeloma cell lines examined showed constitutively active IkB kinase (IKK), IkBα phosphorylation and constitutively active NF-kB. Curcumin, a chemopreventive agent, suppressed constitutive IkBα phosphorylation through inhibition of IKK activity and downregulated NF-kB. Curcumin also downregulated expression of NF-kB-regulated gene products such as IkBα, Bcl-2, Bcl-xL, cyclin D1 and interleukin-6. Consequently, curcumin suppressed multiple myelona cell proliferation and arrested cells at the G1/S phase of the cell cycle. Curcumin also induced apoptosis and chemosensitivity to vincristine. Overall, results presented herein provide a molecular basis for the treatment of multiple myelona patients with this pharmacologically safe agent.
priorityDate 2002-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399636
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID249332
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395834
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399637
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5978
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID969516
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395833

Total number of triples: 41.